Top Medical News
Tirzepatide: A winning weight-loss therapy for nondiabetic, obese adults
Roshini Claire Anthony, Yesterday

Non-diabetic overweight or obese adults experienced a greater reduction in weight and cardiometabolic measures with the addition of tirzepatide to their lifestyle interventions, findings of the SURMOUNT-1 trial showed.

SGLT2is reduce serious hyperkalaemia risk in T2D, CKD patients
Audrey Abella, 3 days ago
Sodium-glucose cotransporter 2 inhibitors (SGLT2is) consistently reduced the risk of serious hyperkalaemia (serum potassium [K+] ≥6.0 mmol/L) without increasing the risk of hypokalaemia (serum K+ ≤3.5 mmol/L) in individuals with type 2 diabetes (T2D) at high cardiovascular (CV) risk, or in those with chronic kidney disease (CKD), a meta-analysis has shown.
Late-afternoon intake of high-energy supplements may do more harm than good in women
Stephen Padilla, 4 days ago
Women with lower body mass index (BMI) who consume high-energy oral nutritional supplements (ONS) late in the afternoon experience only a partial and short-lived energy intake suppression, which increases their total energy intake but has a harmful effect on measures of insulin sensitivity, results of a study have shown.
NAFLD linked to heightened type 2 diabetes risk
4 days ago
Children with nonalcoholic fatty liver disease (NAFLD) are at an increased risk of type 2 diabetes, a study reports. Other risk factors for T2D include severity of liver histology, body mass index, and female sex.
Rapid childhood growth rate tied to elevated risk of islet autoimmunity, T1D development
Stephen Padilla, 5 days ago
Children who grow in height fast appears to have a higher risk of islet autoimmunity (IAA) and rapid progression to type 1 diabetes (T1D), a study has found.
Normal weight obesity in adolescents tied to cardiometabolic risk
5 days ago
Adolescents with normal weight obesity (NMO) may present with several cardiometabolic risk factors, putting them at greater risk of developing vascular events or diabetes, suggests a recent study.
Special Reports
Empagliflozin: A new dawn for heart failure treatment across the ejection fraction spectrum
06 Jun 2022

Initially approved to improve glycaemic control and reduce cardiovascular death in adults with type 2 diabetes (T2D), the SGLT-2* inhibitor empagliflozin reduced hospitalization for heart failure (HFH) or cardiovascular death and delayed renal function decline when added to recommended therapy in patients with heart failure and reduced ejection fraction (HFrEF) in the EMPEROR-Reduced** trial. The EMPEROR-Preserved** trial has now shown that the benefits of empagliflozin extend to patients with heart failure and preserved ejection fraction (HFpEF).

Early and consistent: Breakthrough results in HFpEF similar to HFrEF
14 Jan 2022
HFpEF represents a significant unmet need in CV medicine due to its prevalence, poor prognosis, and the absence of clinically proven therapeutic options. The EMPEROR-Preserved trial demonstrated the continuous clinical benefits in cardiorenal outcomes of empagliflozin in adults with HFpEF, which were consistent with the observations in adults with HFmrEF/ HFpEF in the EMPEROR-reduced trial. The combined results of the EMPEROR trials establish empagliflozin’s efficacy in heart failure regardless of ejection fraction – and if approved, empagliflozin would become the first and only clinically proven therapy to improve outcomes for the full spectrum of the disease. Therefore, empagliflozin offers a new hope for people living with heart failure.
EMPEROR-Preserved: The first successful trial to improve outcomes in HFpEF
18 Nov 2021
Heart failure with preserved ejection fraction (HFpEF) represents a significant unmet medical need. The EMPEROR-Preserved trial aimed to assess the impact of empagliflozin on cardiovascular outcomes in patients with HFpEF. On 27 August 2021, during the hotline session of the 2021 ESC Virtual Congress, the main results of the EMPEROR-Preserved trial were presented by Professor Stefan Anker, principal investigator of the study, and heart failure specialist at Charité Berlin, Germany.
Clinical benefits of flash glucose monitoring with FreeStyle Libre™
15 Sep 2021
Various studies have shown the beneficial effects of the FreeStyle Libre™ flash glucose monitoring system for the continuous monitoring of glucose levels in type 1 and type 2 diabetes (T1D and T2D) patients. While clinical trials have demonstrated a reduced time in hypoglycaemia, fewer hypoglycaemic events per day, and significant reduction in glycated haemoglobin (HbA1c), real-world data have shown improved glycaemic control in these patients.
Optimising glycaemic control with FreeStyle Libre™ for better patient management
15 Sep 2021
The FreeStyle Libre™ flash glucose monitoring system includes a sensor which automatically measures and continuously stores up to 8 hours of glucose readings, allowing patients to monitor their glucose levels without the need for painful finger pricks. Physicians play an important role in reviewing and analysing glucose data that is available through LibreView to support patient management.
Conference Reports
Tirzepatide: A winning weight-loss therapy for nondiabetic, obese adults
Roshini Claire Anthony, 25 Jun 2022

Non-diabetic overweight or obese adults experienced a greater reduction in weight and cardiometabolic measures with the addition of tirzepatide to their lifestyle interventions, findings of the SURMOUNT-1 trial showed.

Semaglutide reduces long-term T2D risk in overweight/obese patients
Elaine Soliven, 21 Jun 2022
Once-weekly injection of semaglutide significantly reduced the 10-year risk of developing type 2 diabetes (T2D) among overweight or obese patients, according to a post hoc analysis of the STEP* 1 and 4 trials presented at ADA 2022.
Dulaglutide: A new horizon for T2D treatment in kids
Roshini Claire Anthony, 18 Jun 2022

A once-weekly subcutaneous dose of the GLP-1* receptor agonist dulaglutide successfully controlled glycaemic levels in youths with type 2 diabetes (T2D) being treated with lifestyle modification with or without metformin or insulin, results of the multinational, phase III AWARD-PEDS** study showed.

EMPRISE shows CV efficacy, safety of empagliflozin in routine care
Audrey Abella, 16 Jun 2022
The final analysis of the 5-year monitoring EMPRISE* programme presented at ADA 2022 demonstrated the cardiovascular (CV) efficacy of empagliflozin in patients with type 2 diabetes (T2D), with a safety profile that aligns with existing evidence.
‘Digital Twin’ tech reverses type 2 diabetes, fixes metabolic disruptions
Jairia Dela Cruz, 14 Jun 2022
A novel artificial intelligence platform that integrates multidimensional data to deliver precision nutrition and health recommendations not only helps to induce remission in type 2 diabetes but also to normalize a range of glycaemic and extraglycaemic parameters, as shown in a study presented at the 82nd American Diabetes Association (ADA) Scientific Sessions.
Higher dairy intake tied to lower T2D risk
Audrey Abella, 14 Jun 2022
Higher consumption of dairy products is associated with a lower risk of type 2 diabetes (T2D) among US adults, according to a nationally representative study presented at ADA 2022.
CREATE: ‘Open-source’ automated insulin delivery gets good results in T1D
Jairia Dela Cruz, 13 Jun 2022

Automating insulin delivery with an open-source algorithm that is run on a smartphone proves safe and effective in the management of type 1 diabetes (T1D), as shown in the results of Community Derived Automated Insulin Delivery (CREATE) trial.